LLY

Eli Lilly and Company

NYQ · Healthcare

$1,181.89

$30.90 (+2.68%)up 2.68%

24 September 2026 · delayed 15+ min

C

Quality score76.3 / 100

Cut-offs are the grader's own: 97+ for an A+, below 60 is an F.

Eli Lilly and Company earns a C on excellent profit margins (>20%) and strong ROE (>20%) but high debt-to-equity ratio (>2.0) and high P/E ratio (39.6) - may be overvalued. Good investment opportunity with solid fundamentals.

Model stance BUY Suggested position 6.8% · $680.00 IQInvest estimate
Adjusted for Moderate investors, Medium-term investors 6.8% suggested allocation Change these

These change the suggested position size and the stance, not the category scores. Amount is in dollars.

IQ-LLY-20260924engine v1 · 7-category weighted scorecard

What it is worth, depending who you ask.

Today’s price against the year it has had and the targets analysts publish. Every marker is a reported figure, not a projection of ours.

52-week low

$712.05

Lowest analyst target

$930.00

Today's price

$1,181.89

52-week high

$1,292.65

Mean analyst target

$1,325.39

Highest analyst target

$1,600.00

LLY trades 81% of the way up its 52-week range, between $712.05 and $1,292.65. The mean analyst target of $1,325.39 is 12.1% above today's price.

Today’s price 52-week range Analyst price targets

Scored categories

Financial healthExcellent profit margins (>20%); Strong ROE (>20%); High debt-to-equity ratio (>2.0) 100.023%

Profit margin

33.53%

Net profit per unit of revenue

exceptionalWhat this means

Of every 100 units of revenue, this much survives as profit.

Margins this wide usually mean real pricing power or a moat.

Operating margin

54.22%

Before interest and tax

very highWhat this means

Profit from operations, before interest and tax, per 100 of revenue.

Typical of software and other businesses with little cost per extra sale.

Gross margin

83.40%

After the cost of goods only

highWhat this means

What is left of revenue after only the direct cost of the product.

Little marginal cost per sale, which is what lets software and pharma fund heavy R&D.

Return on equity

102.29%

Profit per unit of shareholder capital

very strongWhat this means

Profit generated per unit of shareholder capital.

Rare when sustained — check whether debt is flattering it, since borrowing shrinks the equity denominator.

Return on assets

20.36%

Profit per unit of assets

very strongWhat this means

Profit generated per unit of everything the company owns.

Usually an asset-light business — the value is in people and brands, not property.

Debt to equity

162.07

Borrowings against equity

heavily gearedWhat this means

Borrowings measured against shareholder capital.

Debt magnifies both good years and bad, and raises the stakes when rates rise.

Current ratio

1.35

Short-term assets over short-term debts

adequateWhat this means

Short-term assets against short-term obligations.

Enough to cover near-term bills.

Quick ratio

0.68

As above, excluding inventory

adequateWhat this means

Short-term assets excluding inventory, against short-term debts.

Near-term obligations are roughly covered without selling inventory.

Revenue growth

47.70%

Year on year

fast-growingWhat this means

Change in revenue against the same period last year.

Rapid growth, though the question is always how long it can hold.

Earnings growth

26.20%

Year on year

strongWhat this means

Change in earnings against the same period last year.

Profit is compounding at a good clip.

Revenue

$42.77B

Trailing twelve months

Free cash flow

$11.07B

Cash left after capital spending

Operating cash flow

$28.08B

Cash from the business itself

Payout ratio

21.69%

Dividends as a share of earnings

conservativeWhat this means

The share of earnings paid out as dividends.

Comfortably covered, with room to keep raising it.

Growth & momentumStrong 1-year return (59.2%) 95.022%

Return, 1 month

-4.20%

Return, 3 months

4.96%

Return, 6 months

29.39%

Return, year to date

9.93%

Return, 1 year

59.22%

Return, 3 years

109.84%

Sharpe ratio

1.15

Return earned per unit of risk

strongWhat this means

Return earned per unit of risk taken.

Above 1 the return has been generous relative to the swings involved.

Win rate

53.91%

Share of days that closed up

consistently positiveWhat this means

The share of trading days that closed higher.

More up days than most shares manage.

Average daily return

0.16%

Best day

14.87%

Worst day

-14.14%

ValuationHigh P/E ratio (39.6) - may be overvalued; High P/B ratio (31.10) 20.018%

P/E ratio

39.65

Price against trailing earnings

highWhat this means

You pay 39.65 for every 1 unit of annual earnings.

Above about 25 the market is paying up for expected growth.

Forward P/E

24.96

Price against forecast earnings

moderateWhat this means

Price against next year's *forecast* earnings.

A conventional range.

PEG ratio

1.16

P/E adjusted for growth

fairWhat this means

P/E divided by the growth rate — it asks whether the price is justified by the growth.

Between 1 and 2 price and growth are roughly in step.

Price to book

31.10

Price against balance-sheet equity

well above bookWhat this means

Price against the accounting value of the company's net assets.

Normal for asset-light businesses, where the value sits in brands and software the balance sheet never records.

Price to sales

13.23

Price against revenue

highWhat this means

Price against revenue — usable when a company has no profit yet.

The price assumes today's revenue will convert into much more profit later.

EV / EBITDA

25.70

Whole-company value against cash earnings

highWhat this means

Whole-company value, debt included, against cash earnings.

Expensive even before interest, tax and depreciation are considered.

Enterprise value

$1.07T

Market value plus debt, minus cash — the price of the whole business

Shares outstanding

891,741,406

Shares the profit is split across

Dividend yield

0.60%

Annual dividend against price

modestWhat this means

Annual dividend as a percentage of the share price.

A small income component.

TechnicalPrice well above 200-day SMA (strong uptrend); RSI in healthy range (30-70) 100.015%

RSI (14)

55.5

Above 70 overbought, below 30 oversold

neutralWhat this means

A 0–100 momentum gauge over the last 14 sessions.

The middle band, where most trading days sit.

MACD

-6.92

Momentum against its own trend

MACD histogram

4.28

Positive is bullish

ADX

12.7

Trend strength; above 25 is a real trend

no clear trendWhat this means

Trend strength, regardless of direction.

Below about 20 the price is ranging rather than trending.

20-day average

$1,151.40

50-day average

$1,176.11

200-day average

$1,065.72

Price vs 50-day

0.49%

Price vs 200-day

10.90%

Bollinger upper

$1,191.71

Bollinger lower

$1,111.09

Average true range

32.03

Typical daily trading range

Stochastic %K

81.2

Risk4 measured figures 40.012%

Volatility, annualised

32.78%

How far it swings in a year

normalWhat this means

How far the price typically swings over a year.

A typical range for an individual share.

Beta

0.50

Moves against the wider market

steadier than the marketWhat this means

How much the price moves relative to the wider market.

Tends to move less than the index, in both directions.

Maximum drawdown

-34.48%

Worst peak-to-trough fall

significantWhat this means

The worst peak-to-trough fall in the period measured.

A serious decline, though not unusual over a multi-year window.

Risk category

High

The engine's own banding

Analyst viewAnalyst consensus: Buy; Strong analyst coverage (29 analysts) 90.010%

Consensus

Buy

What covering analysts rate it

Analysts covering

29

Mean price target

$1,325.39

Highest target

$1,600.00

Lowest target

$930.00

Implied upside

12.14%

Target against today's price

meaningfulWhat this means

How far the mean analyst target sits above today's price.

Analysts see real room above today's price.

Price against the S&P 500

180 trading days to 2026-09-24

LLY is 11.6% up over the window, against 10.9% up for the S&P 500 — ahead by 0.7 points.
LLY +11.6%S&P 500 +10.9%
Show the numbers
Sampled across the window. Both columns are rebased to 100 on 2026-01-06, so they can be compared directly.
DateCloseLLY rebasedS&P 500 rebased
2026-01-06$1,058.92100.0100.0
2026-01-28$1,018.8896.2100.5
2026-02-19$1,020.0096.398.8
2026-03-12$974.1792.096.1
2026-04-02$932.6488.194.8
2026-04-24$881.1883.2103.2
2026-05-15$1,003.4894.8106.7
2026-06-08$1,147.51108.4106.6
2026-06-30$1,197.71113.1108.0
2026-07-22$1,161.35109.7108.0
2026-08-12$1,218.53115.1111.6
2026-09-02$1,160.08109.6110.4

How the score was built

Each category is scored 0–100, then multiplied by its weight. The seven contributions sum to the quality score.
CategoryScoreWeightContribution
Financial health100.023%23.0
Growth & momentum95.022%20.9
Valuation20.018%3.6
Technical100.015%15.0
Risk40.012%4.8
Analyst view90.010%9.0
ESG50.00%0.0
Quality score100%76.3

ESG is scored but carries no weight in this grade. Add ?esg=1 to the address to include it — the engine then redistributes weight across the other six, so the whole scorecard changes, not just one row.

Argue with the model

Every other grader hands you a number. This one hands you the model.

Move a slider, press Recalculate, and the grade is rebuilt from the same category scores. Nothing is hidden: the scores are the engine's, only the weighting is yours.

What each model believes. Pick one above, or set your own sliders below.
ModelThe emphasis
IQInvest defaultThe engine's own weighting: financial health 23% and performance 22% lead, valuation 18%, then technicals, risk and analysts.
Value investorPrice against worth dominates: valuation 40%, financial health 25%. Chart signals count for almost nothing.
Growth investorMomentum first: performance 40% and technicals 20%. Whether the price is fair today gets just 5%.
Sleep at nightStability over everything: risk 35% and financial health 30% together outweigh all other categories combined.
ChartistThe tape over the fundamentals: technicals 45% and performance 25%. Valuation is nearly ignored.
18%
23%
22%
12%
15%
10%
0%

These are IQInvest's own weights, totalling 100%.

Your grade

C

76.3 / 100

Identical to the IQInvest grade.

All 66 metricsOne flat sortable table, for when you want everything at once.
Metric Category Value Source
20-day averageTechnical$1,151.40Yahoo Finance
200-day averageTechnical$1,065.72Yahoo Finance
50-day averageTechnical$1,176.11Yahoo Finance
52-week highMarket data$1,292.65Yahoo Finance
52-week lowMarket data$712.05Yahoo Finance
ADXTechnical12.7Yahoo Finance
Analysts coveringAnalyst view29Yahoo Finance
Average daily returnGrowth & momentum0.16%Yahoo Finance
Average true rangeTechnical32.03Yahoo Finance
Average volumeMarket data2,667,658Yahoo Finance
Best dayGrowth & momentum14.87%Yahoo Finance
BetaRisk0.50Yahoo Finance
Bollinger lowerTechnical$1,111.09Yahoo Finance
Bollinger upperTechnical$1,191.71Yahoo Finance
ConsensusAnalyst viewBuyYahoo Finance
Current ratioFinancial health1.35Yahoo Finance
Day highMarket data$1,197.75Yahoo Finance
Day lowMarket data$1,151.01Yahoo Finance
Debt to equityFinancial health162.07Yahoo Finance
Dividend yieldValuation0.60%Yahoo Finance
Earnings growthFinancial health26.20%Yahoo Finance
EmployeesMarket data50,000Yahoo Finance
Enterprise valueValuation$1.07TYahoo Finance
EV / EBITDAValuation25.70Yahoo Finance
Forward P/EValuation24.96Yahoo Finance
Free cash flowFinancial health$11.07BYahoo Finance
Gross marginFinancial health83.40%Yahoo Finance
Highest targetAnalyst view$1,600.00Yahoo Finance
Implied upsideAnalyst view12.14%Yahoo Finance
Lowest targetAnalyst view$930.00Yahoo Finance
MACDTechnical-6.92Yahoo Finance
MACD histogramTechnical4.28Yahoo Finance
Maximum drawdownRisk-34.48%Yahoo Finance
Mean price targetAnalyst view$1,325.39Yahoo Finance
OpenMarket data$1,156.67Yahoo Finance
Operating cash flowFinancial health$28.08BYahoo Finance
Operating marginFinancial health54.22%Yahoo Finance
P/E ratioValuation39.65Yahoo Finance
Payout ratioFinancial health21.69%Yahoo Finance
PEG ratioValuation1.16Yahoo Finance
Previous closeMarket data$1,150.99Yahoo Finance
Price to bookValuation31.10Yahoo Finance
Price to salesValuation13.23Yahoo Finance
Price vs 200-dayTechnical10.90%Yahoo Finance
Price vs 50-dayTechnical0.49%Yahoo Finance
Profit marginFinancial health33.53%Yahoo Finance
Quick ratioFinancial health0.68Yahoo Finance
Return on assetsFinancial health20.36%Yahoo Finance
Return on equityFinancial health102.29%Yahoo Finance
Return, 1 monthGrowth & momentum-4.20%Yahoo Finance
Return, 1 yearGrowth & momentum59.22%Yahoo Finance
Return, 3 monthsGrowth & momentum4.96%Yahoo Finance
Return, 3 yearsGrowth & momentum109.84%Yahoo Finance
Return, 6 monthsGrowth & momentum29.39%Yahoo Finance
Return, year to dateGrowth & momentum9.93%Yahoo Finance
RevenueFinancial health$42.77BYahoo Finance
Revenue growthFinancial health47.70%Yahoo Finance
Risk categoryRiskHighYahoo Finance
RSI (14)Technical55.5Yahoo Finance
Shares outstandingValuation891,741,406Yahoo Finance
Sharpe ratioGrowth & momentum1.15Yahoo Finance
Stochastic %KTechnical81.2Yahoo Finance
Volatility, annualisedRisk32.78%Yahoo Finance
VolumeMarket data2,408,724Yahoo Finance
Win rateGrowth & momentum53.91%Yahoo Finance
Worst dayGrowth & momentum-14.14%Yahoo Finance
Add to portfolio Compare Peers Set a price target

Yahoo Finance via yfinance · delayed 15 minutes or more